Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 1/20 | 0.67 |
| ▸ | LCK | P06239 | 11/20 | 0.53 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3943412 | 0.90 | LCK (0.61) | CLK1LCKCRBNNPC1RAB9A | |
| SCHEMBL30263005 | 0.90 | LCK (0.61) | CLK1LCKCRBNNPC1RAB9A | |
| SCHEMBL31119647 | 0.86 | DYRK1A (0.67) | CLK1LCKCRBNDYRK1ANPC1 | |
| SCHEMBL18645938 | 0.85 | DYRK1A (0.67) | LCKCRBNDYRK1ANPC1RAB9A | |
| SCHEMBL21496430 | 0.84 | LCK (0.57) | LCKCRBNDYRK1ANPC1RAB9A | |
| SCHEMBL6643291 | 0.81 | NPC1 (0.67) | LCKDYRK1ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3953825 | 0.81 | ACP1 (0.60) | LCKDYRK1ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL31395897 | 0.80 | LCK (0.54) | CLK1LCKNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20678945 | 0.79 | CLK1 (0.76) | CLK1DYRK1ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17090573 | 0.78 | LCK (0.69) | LCKDYRK1ANPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514460-B2 | Benzazole analogues and uses thereof | 4SC AG (DE) | 2009-04-07 | — | — | US | disclosed |
| EP-1885719-A1 | 2,5- AND 2,6-DISUBSTITUTED BENZAZOLE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | 4SC AG (DE) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006066795-A1 | 2,5- AND 2,6-DISUBSTITUTED BENZAZOLE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | 4SC AG (DE) | 2006-06-29 | — | — | WO | disclosed |
| EP-1674467-A1 | 2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors | 4SC AG (DE) | 2006-06-28 | — | — | EP | disclosed |
| US-20060135782-A1 | Benzazole analogues and uses thereof | 4SC AG (DE) | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135782-A1 | Benzazole analogues and uses thereof | DCK, SBK3, DAPK3 | CLK1 365/4885LCK 325/4885CRBN 1204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.